Moreover, EZH2 has been reported to activate PI3K/AKT pathway and induce acquired resistance in NSCLC [14], and consistent with these findings, we found that inhibition of the EZH2 led to a slight downregulation of AKT and p-AKT levels (Fig. 3I). The gene discussed is AKT1; the disease is non-small cell lung carcinoma.